<SEC-DOCUMENT>0001013762-23-003933.txt : 20231016
<SEC-HEADER>0001013762-23-003933.hdr.sgml : 20231016
<ACCEPTANCE-DATETIME>20231016061644
ACCESSION NUMBER:		0001013762-23-003933
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20231015
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231016
DATE AS OF CHANGE:		20231016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MoonLake Immunotherapeutics
		CENTRAL INDEX KEY:			0001821586
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39630
		FILM NUMBER:		231326158

	BUSINESS ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
		BUSINESS PHONE:		41 41 510 8022

	MAIL ADDRESS:	
		STREET 1:		DORFSTRASSE 29
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Helix Acquisition Corp
		DATE OF NAME CHANGE:	20200818
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea186779-8k_moonlake.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:MLTX="http://moonlaketx.com/20231015">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_MLTX_moonlaketx.com_20231015 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20231015_20231015 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001821586 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:EntityCentralIndexKey">0001821586</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mltx-20231015.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-10-15">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-15</xbrli:startDate>
        <xbrli:endDate>2023-10-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b></b></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20231015__20231015_zLY189qcFXj6"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>PURSUANT TO SECTION 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_901_edei--DocumentPeriodEndDate_c20231015__20231015_zhVUfB56TME6"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">October 15, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img src="image_001.jpg" alt="" />&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20231015__20231015_zPmJgkAY1zy1"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:EntityRegistrantName">MOONLAKE IMMUNOTHERAPEUTICS</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20231015__20231015_zxBrBGgoGHu4"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Cayman
    Islands</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20231015__20231015_zWpB2PQkJCF7"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:EntityFileNumber">001-39630</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20231015__20231015_zhI82TIUAir9"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:EntityTaxIdentificationNumber">98-1711963</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction<br />
 of Incorporation)</span></td>
    <td>&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td>&#160;</td>
    <td style="text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer <br />
Identification No.)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20231015__20231015_zyhSQWqoDXvi"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:EntityAddressAddressLine1">Dorfstrasse 29</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20231015__20231015_zh79DHMHOLW5"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:EntityAddressPostalZipCode">6300</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressCityOrTown_c20231015__20231015_zJwdwqJ8rSL9"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:EntityAddressCityOrTown">Zug</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_900_edei--EntityAddressCountry_c20231015__20231015_zsyD5vJaTuXa"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Switzerland</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices and Zip
Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><span id="xdx_907_edei--CityAreaCode_c20231015__20231015_z9b0m3P3UYPh"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:CityAreaCode">41</ix:nonNumeric></span> <span id="xdx_900_edei--LocalPhoneNumber_c20231015__20231015_zNHYRszuCYh9"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:LocalPhoneNumber">415108022</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&#8217;s Telephone Number, Including
Area Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="background-color: white"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="background-color: white">(Former Name
or Former Address, if Changed Since Last Report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="background-color: white">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20231015__20231015_zH3NmxeMo1W3"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)</span></td>
</tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SolicitingMaterial_c20231015__20231015_zcLDNJHtbC96"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr></table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--PreCommencementTenderOffer_c20231015__20231015_z6kTHL6B4wa7"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20231015__20231015_zWKiL5dAe9Ya"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify"><span style="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="white-space: nowrap; text-align: center; padding-bottom: 1.5pt; width: 2%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20231015__20231015_zIRkKlkVwA24"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:Security12bTitle">Class A ordinary share, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20231015__20231015_zgfwLrOFxh59"><ix:nonNumeric contextRef="AsOf2023-10-15" name="dei:TradingSymbol">MLTX</ix:nonNumeric></span></span></td>
    <td style="text-align: center; vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center; padding-right: 5.4pt; padding-left: 5.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_90D_edei--SecurityExchangeName_c20231015__20231015_zQR8NoAHTwwj"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20231015__20231015_z8XszRdqjxt4"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityExTransitionPeriod_c20231015__20231015_z2UrW2bvzZfk"><ix:nonNumeric contextRef="AsOf2023-10-15" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01. Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">On October 15, 2023, MoonLake Immunotherapeutics
(the &#8220;Company&#8221;) issued a press release announcing positive 24-week top-line results from its global Phase 2 MIRA trial (M1095-HS-201)
evaluating the efficacy and safety of the Nanobody&#174; sonelokimab in patients with moderate-to-severe hidradenitis suppurativa. The
Company will host a webcast today, Monday, October 16, 2023 at 8:00 am, Eastern Time, to discuss the data results.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">A copy of the press release
is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item
7.01 of this Current Report on Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act,
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange
Act or the Securities Act, regardless of any general incorporation language in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(d) <i>Exhibits</i>. The following exhibits are
being furnished herewith:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 9%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="text-align: left; padding-bottom: 1.5pt; width: 1%; vertical-align: bottom">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left; width: 90%; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Title or Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea186779ex99-1_moonlake.htm">Press Release, dated October 15, 2023</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MOONLAKE IMMUNOTHERAPEUTICS</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 1.5pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#160;</span><b>October
    16, 2023</b></td>
    <td style="padding-bottom: 1.5pt; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Matthias Bodenstedt</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Matthias Bodenstedt</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">2</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2WnK1vPEyKYksQiS6XXKMJd2R2e3vkXrLNiUaBobhnO8cIUJR0Fp3yHBaViXU2A+dcggVtshozugd+Wabgb8VXrR1rIwb3x+Yk2fQM+kskcoLo/WuLTYZxDKK0yiZg4yzdAGHnQi+ek6m1Q0ap1UHyjRwYBpYo1P8mhJq9SRD/WusOiJbTcbHzeQkvyGRcQJ7uqsH8dVCWeYiCMcJRMF0G741N+uoh1WHve+yE/rf4AMUiElE -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea186779ex99-1_moonlake.htm
<DESCRIPTION>PRESS RELEASE, DATED OCTOBER 15, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MoonLake
Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody<SUP>&reg;</SUP> sonelokimab
as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (HS)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance
                                            treatment with sonelokimab dosed every 4 weeks (Q4W), demonstrated that 57% of patients achieved
                                            HiSCR75 at week 24, increasing the landmark week 12 responses (primary endpoint) by over
                                            10 ppt (percentage points)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            depth of responses continued to increase from week 12 to week 24 across several scores, including
                                            over 14 ppt increases in HiSCR90 and IHS4-90 (to approximately 40% of patients) &ndash; 1
                                            in every 4 patients reached inflammatory remission with IHS4-100, reflecting 100% reduction
                                            in abscesses, nodules and draining tunnels</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rates
                                            of complete resolution of inflammatory nodules and abscesses (AN 100) and draining tunnels
                                            (DT 100) increased between week 12 and 24</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
                                            responses translated to robust improvements in health related quality of life (DLQI), skin
                                            pain (NRS30), and self-reported absent or minimal disease (PGI-S)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maintenance
                                            dosing, placebo cross-overs to sonelokimab 120mg or 240mg, as well as pharmacokinetic data,
                                            confirm 120mg as the dose with optimal benefit-risk profile</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            non-responders to adalimumab at week 12 switching to sonelokimab resulted in HiSCR75 response
                                            rates similar to those randomized to sonelokimab at baseline</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safety
                                            results of sonelokimab were consistent with previously reported studies with no new observed
                                            safety signals</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Topline
                                            data will be discussed on <B>16 October, at 2pm CEST/ 8am EDT</B>, via webcast (registration
                                            link below)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ZUG,
Switzerland,&nbsp;</B>October 15 2023 &ndash; MoonLake Immunotherapeutics (&ldquo;MoonLake&rdquo;; Nasdaq: MLTX), a clinical-stage biotechnology
company focused on creating next-level therapies for inflammatory diseases, today announced positive 24-week top-line results from its
global Phase 2 MIRA trial showing that maintenance treatment with its Nanobody<SUP>&reg;</SUP>&nbsp;sonelokimab led to further improvements
in HiSCR75 response rates and other clinically relevant outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jorge
Santos da Silva,&nbsp;PhD, Founder and&nbsp;Chief Executive Officer at MoonLake, said:&nbsp;</B><I>&ldquo;The overall data package created
with the MIRA trial establishes MoonLake&rsquo;s position as a leading innovator in the Immunology and Inflammation (I&amp;I) and IL-17
space. We have consistently observed best-in-class clinical activity with our Nanobody<SUP>&reg; </SUP>sonelokimab for hidradenitis suppurativa
and these results demonstrate its effect on a number of clinically meaningful endpoints. In June we elevated the bar for clinical response
to HiSCR75 as the primary endpoint. We have now advanced to demonstrating even deeper responses (such as HiSCR90, AN 100 and DT 100)
and on scores that are important for patients, such as complete inflammatory remission with IHS4-100 and absent or minimal disease activity
as reported by patients (PGI-S). Importantly, the results have confirmed our view that 120mg is the optimal dose and we are on track
to discuss our Phase 3 development plans with the FDA by the end of this year.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
24-week results follow the positive 12-week results, announced in June 2023 and subsequently presented at the European Academy of Dermatology
and Venereology Congress in October 2023, in which the primary endpoint was met with 29 percentage points delta versus placebo (p=0.0002)
at week 12. The MIRA trial set a landmark milestone <FONT STYLE="background-color: white">as the first placebo-controlled randomized
trial in HS to use </FONT>Hidradenitis Suppurative Clinical Response 75 (HiSCR75) <FONT STYLE="background-color: white">as the primary
endpoint.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
24-week results show that </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ongoing treatment with sonelokimab
120mg and 240mg dosed Q4W, further increased HiSCR75 response rates compared to week 12. 57% of patients continuously treated with 120mg
achieved a HiSCR75 response (more than 10 ppt improvement from Week 12) and 38% achieved HiSCR90 (more than 14ppt improvement versus
week 12). The IHS4 score, which encompasses changes in all active HS lesions (nodules, abscesses, draining tunnels), decreased by 65%
in patients treated with the 120mg maintenance dose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rates
of complete resolution of inflammatory nodules and abscesses (AN 100) together with complete resolution of draining tunnels (DT 100)
also increased between week 12 and 24 (31% and 49% of patients achieving this high level of response at week 24 with 120mg respectively,
an increase of up to 15 ppt). Complete inflammatory remission (IHS4-100) was achieved in 1 in 4 patients (24%) treated with 120mg at
week 24. Clinical responses translated to profound improvements in patient-reported outcomes at 24 weeks including quality of life (DLQI),
pain (NRS30), and patient global impression of severity. 43% of patients reached self-reported absent or minimal disease activity on
the PGI-S scale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results
obtained with placebo patients re-randomized to sonelokimab 120mg or 240mg in Part B, after the primary analysis, replicated the
dose responses observed in Part A. Difficult-to-treat subgroup analysis (e.g., in Hurley stage III patients or those previously
exposed to biologics) confirms the advantage of the 120mg dose. Similarly, pharmacokinetics (PK) analysis support the use of the
monthly maintenance 120mg dose. For patients who were inadequate responders to adalimumab at week 12 switching to sonelokimab
resulted in HiSCR75 response rates similar to responses in those randomized to sonelokimab at baseline. Sonelokimab provided better
durability of response compared to that observed with adalimumab in other studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
safety profile of sonelokimab was consistent with previously reported studies with no new safety signals observed. Overall, sonelokimab
continues to show a favorable safety profile, in line with the known profile of IL-17 inhibitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the efficacy and safety results, Q4W maintenance dosing of sonelokimab 120mg has been confirmed in the Company&rsquo;s view as the
optimal dose, in terms of speed and depth of response, and overall benefit-risk profile, for progression into Phase 3 development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Kristian
Reich,&nbsp;MD, PhD,</B>&nbsp;<B>Founder and Chief Scientific Officer at MoonLake,&nbsp;commented:</B>&nbsp;&ldquo;<I>These positive
results at 24 weeks, which build upon the initial 12-week results, show that the clinical activity and responses with longer exposure
of sonelokimab deepen over time in patients with hidradenitis suppurativa as we saw in psoriasis. It underscores the advantage of treating
patients with a smaller biologic with albumin-binding capacity to inhibit IL-17A and IL-17F for the treatment of inflammatory diseases
and highlights the impact our Nanobody<SUP>&reg; </SUP>sonelokimab has on a breadth of outcomes that matter for patients with HS, beyond
HiSCR75. MIRA creates, in my opinion, a unique Phase 2 data package, for a disease that has proven to be extremely challenging to treat.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joslyn
Kirby, MD, MEd, MS, Professor and Vice Chair for Education, Department of Dermatology at Penn State, and President of the Hidradenitis
Suppurativa Foundation added:</B>&nbsp;<I>&ldquo;Hidradenitis suppurativa is a chronic, inflammatory condition that has profound impacts
on a patients&rsquo; lives. As a clinician who works with people with HS, there is an urgent need for new treatment options that give patients
high levels of response and meaningful improvements in their condition. The high clinical response rates observed with sonelokimab in
the Phase 2 MIRA trial, which are accompanied by critical improvements in patient reported outcomes, are exciting, demonstrating its
promise as a potential future treatment option.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
topline data will be discussed on <B>16 October 2023 at 2pm CEST/ 8am EDT before the Nasdaq market opens, via webcast </B>at:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
Link:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://onlinexperiences.com/Launch/QReg/ShowUUID=172DFCAF-36D9-4C44-BF2C-982C999BE61F&amp;LangLocaleID=1033&amp;GroupID=Onyx</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Login
Link: (for those already registered)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://onlinexperiences.com/Launch/Event/ShowKey=241209</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
replay of the webcast and the presentation document will be made available at&nbsp;https://ir.moonlaketx.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
results from the MIRA trial will be submitted for publication in a peer-reviewed medical journal and for presentation at an upcoming
scientific meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
has already been successfully assessed in a randomized, placebo-controlled, Phase 2b trial (NCT03384745) in 313 patients with moderate-to-severe
plaque-type psoriasis in which it demonstrated a rapid and durable skin clearance (PASI100) with no unexpected safety findings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
is currently also being evaluated in a Phase 2 trial (NCT05640245), &lsquo;ARGO&rsquo;, in patients with active psoriatic arthritis with
the primary end-point readout expected in early November this year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
is not yet approved for use in any indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-&nbsp;Ends
&ndash;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Hidradenitis Suppurativa</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hidradenitis
suppurativa is a severely debilitating chronic skin condition resulting in irreversible tissue destruction. HS manifests as painful inflammatory
skin lesions, typically around the armpits, groin, and buttocks. Over time, uncontrolled and inadequately treated inflammation can result
in irreversible tissue destruction and scarring. The disease affects 0.05&ndash;4.1% of the global population, with three times more
females affected than males. Onset typically occurs in early adulthood and HS has a profound negative impact on quality of life, with
a higher morbidity than other dermatologic conditions. There is increasing scientific evidence to support IL-17A- and IL-17F-mediated
inflammation as a key driver of the pathogenesis of HS, with other identified risk factors including genetics, cigarette smoking, and
obesity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the MIRA trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
MIRA trial (M1095-HS-201) is a global, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of the
Nanobody<SUP>&reg;</SUP>&nbsp;sonelokimab, administered subcutaneously, in the treatment of adult patients with active moderate-to-severe
hidradenitis suppurativa. The trial recruited 234 patients, with the aim to evaluate two different doses of sonelokimab (120mg and 240mg)
with placebo control and adalimumab as an active reference arm. The primary endpoint of the trial is the percentage of participants achieving
Hidradenitis Suppurativa Clinical Response 75 (HiSCR75), defined as a &ge;75% reduction in total abscess and inflammatory nodule (AN)
count with no increase in abscess or draining tunnel count relative to baseline. The trial also evaluated a number of secondary endpoints,
including the proportion of patients achieving HiSCR50, the change from baseline in International Hidradenitis Suppurativa Severity Score
System (IHS4), the proportion of patients achieving a Dermatology Life Quality Index (DLQI) total score of &le;5, and the proportion
of patients achieving at least 30% reduction from baseline&nbsp;in Numerical Rating Scale (NRS30) in the Patient&rsquo;s Global Assessment
of Skin Pain (PGA Skin Pain). Further details are available at:&nbsp;https://www.clinicaltrials.gov/ct2/show/NCT05322473.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About&nbsp;Sonelokimab</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
(M1095) is an investigational ~40 kDa humanized Nanobody<SUP>&reg;</SUP>&nbsp;consisting of three VHH domains covalently linked by flexible
glycine-serine spacers. With two domains, sonelokimab selectively binds with high affinity to IL-17A and IL-17F, thereby inhibiting the
IL-17A/A, IL-17A/F, and IL-17F/F dimers. A third central domain binds to human albumin, facilitating further enrichment of sonelokimab
at sites of inflammatory edema.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
is currently being assessed in two ongoing trials, the Phase 2 MIRA trial in HS and the Phase 2 ARGO trial in PsA. In June 2023, the
MIRA trial met its primary endpoint, the Hidradenitis Suppurativa Clinical Response (HiSCR) 75, which is a higher measure of clinical
response versus the HiSCR50 measure used in other clinical trials. Following the positive 12-week results, positive results at 24 weeks
have now been announced in October 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sonelokimab
has been assessed in a randomized, placebo-controlled Phase 2b study in 313 patients with moderate-to-severe plaque-type psoriasis. Sonelokimab
demonstrated a rapid and durable clinical response (Investigator&rsquo;s Global Assessment Score 0 or 1, Psoriasis Area and Severity
Index 90/100) in patients with moderate-to-severe plaque-type psoriasis. Sonelokimab was generally well tolerated, with a safety profile
similar to the active control, secukinumab (Papp KA, et al. Lancet. 2021; 397:1564-1575).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an earlier Phase 1 study in patients with moderate-to-severe plaque-type psoriasis, sonelokimab has been shown to decrease (to normal
skin levels) the cutaneous gene expression of pro-inflammatory cytokines and chemokines (Svecova D. J Am Acad Dermatol. 2019;81:196&ndash;203).
Currently, a global phase 2 trial in psoriatic arthritis (NCT05640245, M1095-PSA-201, &ldquo;ARGO&rdquo;) including multiple arms and
over 200 patients is ongoing (announced on Dec 14, 2022).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
MoonLake Immunotherapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MoonLake
Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, a novel investigational Nanobody<SUP>&reg;</SUP>&nbsp;for
the treatment of inflammatory disease, to revolutionize outcomes for patients. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the
IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. The company&rsquo;s focus is on inflammatory diseases with a major unmet
need, including hidradenitis suppurativa and psoriatic arthritis &ndash; conditions affecting millions of people worldwide with a large
need for improved treatment options. MoonLake was founded in 2021 and is headquartered in Zug, Switzerland. Further information is available
at&nbsp;www.moonlaketx.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Nanobodies<SUP>&reg;</SUP></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nanobodies<SUP>&reg;</SUP>&nbsp;represent
a new generation of antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding variable
regions of heavy-chain-only antibodies (VHH). Nanobodies<SUP>&reg;</SUP>&nbsp;have a number of potential advantages over traditional
antibodies, including their small size, enhanced tissue penetration, resistance to temperature changes, ease of manufacturing, and their
ability to be designed into multivalent therapeutic molecules with bespoke target combinations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms Nanobody<SUP>&reg;</SUP>&nbsp;and Nanobodies<SUP>&reg;</SUP>&nbsp;are trademarks of Ablynx, a Sanofi company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cautionary
Statement Regarding Forward Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains certain &ldquo;forward-looking statements&rdquo; within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding MoonLake&rsquo;s expectations, hopes,
beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: plans for clinical trials
and research and development programs; and the anticipated timing of the results from those trials, including completing the MIRA trial
and commencing a phase 3 trial; and the efficacy of our products, if approved, including in relation to other products. In addition,
any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying
assumptions, are forward-looking statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;possible,&rdquo;
&ldquo;potential,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;should,&rdquo; &ldquo;would&rdquo; and similar expressions
may identify forward-looking statements, but the absence of these words does not mean that such statement is not forward looking.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are based on current expectations and assumptions that, while considered reasonable by MoonLake and its management, as the
case may be, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all
risks and uncertainties. Actual results could differ materially from those anticipated in such forward-looking statements as a result
of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with MoonLake&rsquo;s business
in general and limited operating history, difficulty enrolling patients in clinical trials, and reliance on third parties to conduct
and support its clinical trials, and the other risks described in or incorporated by reference into MoonLake&rsquo;s Annual Report on
Form 10-K for the year ended December 31, 2022 and subsequent filings with the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will
be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance
on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety
by reference to the cautionary statements herein. MoonLake does not undertake or accept any duty to release publicly any updates or revisions
to any forward-looking statements to reflect any change in its expectations or in the events, conditions or circumstances on which any
such statement is based.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MoonLake
Immunotherapeutics Investors</B><BR>
Matthias Bodenstedt, CFO<BR>
info@moonlaketx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MoonLake
Immunotherapeutics Media</B><BR>
Patricia Sousa<BR>
media@moonlaketx.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ICR
Consilium </B><BR>
Mary-Jane Elliott, Namrata Taak, Ashley Tapp<BR>
Tel: +44 (0) 20 3709 5700<BR>
media@moonlaketx.com<BR>
MoonLake@consilium-comms.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  V ,0# 2(  A$! Q$!_\0
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M-^=\9<;+)*G]EY;R3S7W6ZU6$:U"*>O*Z3DHWE=:\[M:5EHS]L/CU_P</_\
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M0T. 93C8 RE'?#[9C/GA[2$9./31[?<2YQ3M=+Y_K<L4445104444 ?Y3/\
MP7(_:&U3]HK_ (*?_M0ZS<:H^H>'OA5XG7X#^#;:.ZFDM]'\/?"VVU/2M6M+
M5I4_=/KWC.?Q%K6LD$DIJ<+'?/8Q0#X0_99_9Z\:_M9?M$?";]G;X=JS^*/B
MSXST'PDFK!9MFCZ/=-&WB[Q%>+'!<RV\.DV9GU&XF@M[EXK&SNI60.BI)Z1_
MP4&M9;7]O']N>UO()H)G_;!_:3NQ"\7D_N=9^+?BB2"\8,5==/;1X6O+=]OF
M&V"/Y W<_;__  ;T^)M#\+_\%>?V4;[Q)JMII-KJUO\ %'PS87%\XMXKCQ%X
MP^#WC+P_HFGHR"0"_P!<U>\CBT*/!^T2W-DLQMWD9(_]/859<*>#?M<E][$X
M#AM9EDRIVJ0GB8\-QS-SQ4$E'%0>*4JDH3Y(^S4X74/>7\SO_A2X@Y,2M'GW
M]G\\]*JPU[6YV^9SU5JC5]8Z2MK_ *,W[&W[$OP(_8;^#/ASX+_ GPAIOAW1
MM(LM*77M?CMXH?%7CS7[*RBM+SQ1XVUVTCM[O7-8O?*,N9O+L8?/FCALHD*X
M^LTMI]F)GCD!")@AF4J$(D*AP9%9V&?W\]V  .I)J6"Y0L$QAG+*J,T:LYC<
M)<"-6<&06I*^?)&'B&X+&\C94:&!C':O\P<5F&,S'$U,=BZ^(JXZHW*<L3.=
M3FF[7E*,Y>\[))<TFHI148QBE$_I*AA\/AZ"PU.A2]BE;EE",FUYR:3?W=6?
MR*?\'(O_  2@^&WQ%^!GB_\ ;W^#/A>Q\*?&KX56$6J_&/3/#=DFFZ3\5OAM
M+JMM8:AJ^O:?8PRQS^+O"$-X-7C\0LEO+?Z59:E->RQO;P6\G\"@4E%?(P_0
M'KUQS_\ 6)K_ %Q_^"H_BCP]X/\ ^"<?[;6L^);JVT_1X_V7?C1HTL]XG[M[
M_7?!&K^'M%M$5UW37&H:YJMEINFQPAY;C4+NV2V1RQ(_R-K;A(E?DIP<#@CV
MSC)_ ?I7]W_1?S[,<VX2S[*,=4Q<ZM#/Z>6Y!CJM6I)X##SAS2AA:DW)TJB;
MNJB;?+)6C9)GX9XF9?AZ&;4Y86-.FY14I126CVZ6UT3?GIM8_P! ?_@T^_:&
MU;X@?L@_&C]GK6-1NKZY^ 7Q8T[4?"XDN,II_@OXFZ.NK_V3%&69[6UM/'&A
M>-I888HO(_LV_MV23[2UQ;6W]!7[>?C/Q;\./V+_ -J+Q[X(\0W_ (6\8>$/
M@7\3O$WAGQ)I.P:AX?UO0_"6H7UCJ5BC[8YKFWN[?SXC,\>'(^93EA_*'_P9
M]6DIU']OR^6TD-O<0_LUV"W8#I!)+:CXZ-?RQ,P&?,EG=$^42L8H3*D<;*]?
MU+_\%*\'_@G[^V2>X_9N^- _\L;637\W>+N48/">-O$.'HQ@J&-XCX>P=>C0
M:A05#,_[ EBE2IQ7+2J2>8XKDG&[@ITTE+D2E^B<,5<3BN%8UJTVZJC4UC>.
MRNG:[ZZ[]_E^=W_!#;]KCX__ !0\ _$;]FK]L#QQ<_$?]HWX-V?P\^)^F?$/
M5)+&VUKXH_ G]H/PI:?$OX;^*YK&UT_2D8:%/J>I>"[IH89;2UGTM;%+V<6Z
M,_Z0?M\?M6Z/^Q?^R;\9?VA=4M9]3U'P;X;D@\$>';5R;KQ/\3?%%Q:>#?AG
MX4LH829KP>(/%^JZ?#Y<"O<"#SYH[=Y(TC/X@?$M9_V/_"?_  1^_P""HOA]
MK/2_"FA?!/\ 9]_9 _:]Q#.EGJ?[/OQ@\$>&D\'^-=4%O$JS/\,/BDUMXCM+
MK4)[8VG]N2Z>DDMK(5'U9^U/>WG[</\ P4^_9E_8ZT::>[^!7[%MCX;_ &Y/
MVEKFRN8CH>L_$!SJD/[,GP_U2&&2[BU(-J$2^/VL;JWLK9M+M3?07-U(((#X
M-?*,-F/$F%SR2IPR6-#'9WFM+"+ZMAH8#(:L8YOE]&,%*-'%9A*G@8X.=--T
M7Q#0]C3J?5K/NHUZ]#+L7@Z<_P#:IZ9;[3WV^9>XZEVO:6=V[I72LVC%_P""
M#OQ3_:_\=>#_ -LOP7^VI\6O$GQ9^+?P9_:8LO EU<^(X;"TE\++JOP<^'7B
MO5O"NEPZ586 T^VTKQ/KFJ6CPQ++%;SVUV(SC9+)^BWQU_X*;_L"_LS>+C\/
MOCO^UC\%/AKXY5+6>Y\'Z[XVTB3Q/IEI=W M(+_7/#^FSZAJ_AVP:Z$D#WNO
MV>FVT)BD>>2.)1(WX7?#[X^^,?V:/@9_P<H_'OP R1>/?A7^U9\4->\+37/F
MM;Z/KH^"'@?3[;5YF0;I8=+>\;Q$ZA'VO&I\MPJJWZP?\$\_V!_V8_@K^R]\
M,;MOASX1^(_Q#^*?@KPW\4OC+\:/B7HVF>-?'OQ:^(WQ$T.S\5>+/%WB?Q5X
MI_X2&\U"77-5UB^N(-/T_4FT#3K81I9V-NP\N6N*L'D\,WS#.<=4]C@(OA^.
M'R_AWEFE/,>&.'LVQDV\QI8>G"'M\QKJBG2O!SC"/-3I<T[RUXGZCE^&H5E&
M59-UGB4Z\K7=N6\HN+?9-K33='Z-_#GXP_#'XP>#]'^(/PJ\<>&?B+X%U^"&
MXT;Q?X,UO2_$/AW4H[BWBN819:MIEW<6=U*Z31*;>"62XAE=8YXHF(%>#_M&
M_M\_L>?LC2Z;:_M)?M$?"_X0:EK,:RZ1H7B[Q3I5MXEU2$M"K3Z=X7M[BY\1
M7UK'YZ,][:Z7-9%-[1W$@1L?D/X8\(^'_P#@GE_P6 B^$_[.^AQ>&/@+^VM^
MRS\7/COXQ^">@6MUIO@+P7\:/@9>QG_A,O"FFS7D^G>&U^(.FW7]G:EHN@Z7
M865K>1M+:0O;LNS>_P""-'[+'PE^,O[/$?\ P4%^.?A7P?\ '']JK]LKQ'X\
M\?\ CCXF^.M&T_QD_A?PM;>./$7AOPU\,/ K^)=/UNR\-^$/ 6E:,EEI]EH5
MKID&HWT>R_>2!B!Y53(<MP%#%YWB\SEBLEI1R"IALIP\:5+B:M'-8YB\13<4
MJN7QE1629A*-24N5/%X!*,[R@=4<QJ5JSP%+DIXQ7OB)QYJ$>5Q3?(Y).]]$
MY==&['[+_ ?]J']G[]J#PH_CC]GKXP^ /C#X3AF:UN];\!^)=)UZWT^]5F#6
M.JV]K<M?:1>;4,B6^J6MG)+&5>$2 UYKX_\ ^"@7[%WPL3XJ/\0_VF?@[X07
MX(>(=)\)?%L:]XXT#3I/ 'BO7M+;6M$\-^(H;J\BFL]:U328YK^VL!&\P@AE
M,ZPLH5OR?_:X^!OP\_86_P""AW[ ?[5/[,FA>'?A/K?[5'QWL?V2/VCOA;X+
ML+;PGX2^,'A/Q7X.U6[\)>-+CP9IPL-$/B?X:WFE(T_B:QTQ+^;[?9PZC"JR
M3R1>(?\ !/;]F3X,_&C_ (+%?\%A?BQ\4O NA>/_ !5\'?C+\.-'^'47C&S_
M .$@T#P[+X^\%R3^(=;L_#NK/>Z%;>*-F@6VG:;XBATW[=8Z=?ZDD"QLP$FV
M&X>RRM@LQSB>85(X##9!',Z&%:@L1]:_M^.52I5:W*E.FJ+<N:$(1YOWMDER
M2SJ9EB'B?[*HNG]?O9XAT[T+6<KJFW:_*G9.734_=G]G']O+]D/]KM-;_P"&
M:OV@_AG\8+OPW%;W/B'2?"?B73IO$&@V=V6%K?ZSX<O9;/7M-LIPK/'<WFG0
MQLHQG>0A^"_"OQZ^-=Y_P78^+/[.%U\1M?F^!>C_ +!WP^^)6C?#!VLO^$4L
M/'NI>.;S2[KQ1#:_8CJ$=[+9V4L+0IJOE%70E^65/"/^"E7P@^%W[,W[8_\
MP2T_:J^$/A+3/AQ\1]:_:V\-_LZ>.KGX>V4/@^S\?_";XC>%?%\4OASQ;I6@
MOIFE^(/[%U 65QIESK-M?2PQ+,%^[#%6]X.D'_$2+\:WV2A4_P"";OPNB.(F
MD&[_ (6/K\^"T(D10$^4EV7+\+NRI/7@>'\.L%F&:T8SGEU3A;B',<LH5IQJ
MXF&+RW/^'\LI3K5HQA&M%8?,<3*48TZ4'-QGS1=.*>5?&RYU3J.*J/B!9<E%
M.-\+)<T%:[_>--)U&[M_9/Z!VO$5HQY<K"7=L=%1D)4C:"0^1YBDR(2-HC1V
M=D"FOS]^)G_!53_@G9\&_B-<_"3XF_MC_ ;P;\0[&33X-2\-ZSX]T6WETFZU
M68VVGV6M:CY[:/HM]<70-M]BU74;.ZAF!%S%"OS5X!_P6V^/GQ%^ _\ P3Y^
M)>K?"_4=>\*>.?BAXP^%WP&TSQ_H&;.]^'ME\7O'>C^#M;\:K+/+;K976GZ1
M<:I9:+.=ZKK&JZ&)Y;6UN+F]L_HS]G[_ ()Z?LB?LX_!;1_@AX"^ WPX/A./
M1HK#Q-?Z_P"#=&\1>(/B+J2QP07_ (E\;Z]J=I>ZIXA\0:^ZSZS)J=QK+3V-
M](KVZ10QF!/F<OP6#AE=#-LU6<3IYM4G3RS"X7#Y?1JX5T525=XV52M.35*5
M:"Y)1C)MW=116GJ8FOBYXQY=@\,Z=91YWB:S4Z/*V[<L=%)M+OHDW:Y]*:#\
M=OA#XI\96WPY\+_$7PIXA\<7OP\TGXM6'AS1=8L]3OM1^&6NZO-H&C>.M/\
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0S]G'O+_P+_@ %%%%: ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  W ,4# 2(  A$! Q$!_\0
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MOQI\'_"OQE_;?\&Q?MC_ +57QP\(:%X^^,7Q7^-6K:SXH:UUOQAIL6OR^$/
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MAO\ ";XO?MF>,=.U;X@_&+4/$_Q)GU.Z^(WQWU>TTZ+4M6U76?#'A+2-?B\
M>"_#5M+%X<N[W3%\.Z;>ZG!<7-_\QZ%9_P#!MK8?#Z;P5XK\&>+OB?XCU2UF
M/BGXT_$C]GO]L?Q'\=_%7B.\4OJ/C/4?BM)\,H/%=AXEO+XMJ"W&@7ND6>GW
M.Q--L;2WBC@7R<OX!P^-P7]KT:G%&:91BL?C,ORNMD'#$,9BL0LM6%I8_,\;
M0Q>9X>CE^"^MXGV. P<\16S;&TX2JU%@N2:.S$<05*-?ZG..583&4L/1Q.+A
MF&:.A1I/$^UGA\+0J4L+4J8FO[&ESXBO&G#"4)24(NO>)_6917X,?\$:_P!J
M>_\ %-I^U1^SS)X^^*OQP^"W[-GQ&\&VO[,WQW^*'@CQ]H'CKQE\%OB3H&K:
MKI'@OQ3-XZT#P]K_ (AUSX3:OX=U?PK/XCOM-M[G4["73'\F*P33@Q7R/$'#
MN-X?S?&936OB)89T)TZ\*52C[;#XO"X?&X6I/#UINOA:TL-BJ2Q&#KMU\'B8
M8C"UG*='GJ>QEV94,QP='&4_W:J^TC*G*<9\E2C5JT*L8U()4ZL%5HS]G6I_
MNZU*5.K"T9\L?XV_^#B/]EO6?V;O^"F_QGUXV,\7@G]HJ6U^/7@G46@9+6ZD
M\7J8O'5C',!Y+W.F?$"Q\2&2",[X-.O=)EE1!=1%_P ??@S\7/'/P$^+'PZ^
M-7PSU9M"\?\ PM\8Z!XX\):H%,D=MK?AW48-2LA=0!XQ=V%Q) +;4;%W$5]8
MS7%G-F&=P?\ 4+_X+._\$O=#_P""FG[,;^&- ;2M$_:%^%,NI^+/@5XLU(K;
MVDNJW5M"FN_#_7[X(TEMX9\=6]E96TUUADT?7K#0M<=)K6PO+.\_RZ/BE\*_
MB+\$OB!XK^%7Q9\&Z_X ^(?@C6+K0O%/A+Q-82Z=J^D:G9OLDAG@E&V6&52E
MQ97ML\]CJ-E-;W^GW-S97-O<2?W[X)\<Y;QQP1@\HQ52A5SG(LMI9+G66UW"
M4\5@*6'>7X7'JC-WKX+'8!4\-B9*,X4L53KX>MR.M0=3^>>.<AQ60Y[6QE*-
M2."Q^)GCL#B:?,E2Q$ZBQ%7#N<?X=>AB.:K23:<Z4J=2'-R5%'_5+_X)J?\
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>BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mltx-20231015.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 86o5s7xRiXhun8uDb31cWaOMSaPty5BxiZkxsmx3HTlqrycqkwHZjyWq9femAXcI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:MLTX="http://moonlaketx.com/20231015" elementFormDefault="qualified" targetNamespace="http://moonlaketx.com/20231015">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://moonlaketx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mltx-20231015_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mltx-20231015_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mltx-20231015_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mltx-20231015_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.20a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://moonlaketx.com/role/Cover" xlink:href="mltx-20231015.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://moonlaketx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140096089282576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 15, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 15,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOONLAKE IMMUNOTHERAPEUTICS<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001821586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1711963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Dorfstrasse 29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Zug<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">6300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">415108022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A ordinary share, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MLTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ea186779-8k_moonlake_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mltx-20231015.xsd" xlink:type="simple"/>
    <context id="AsOf2023-10-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2023-10-15</startDate>
            <endDate>2023-10-15</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-10-15">0001821586</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-10-15">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-10-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-10-15">2023-10-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-10-15">MOONLAKE IMMUNOTHERAPEUTICS</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-10-15">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-10-15">001-39630</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-10-15">98-1711963</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-10-15">Dorfstrasse 29</dei:EntityAddressAddressLine1>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-10-15">6300</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-10-15">Zug</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2023-10-15">CH</dei:EntityAddressCountry>
    <dei:CityAreaCode contextRef="AsOf2023-10-15">41</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-10-15">415108022</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-10-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-10-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-10-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-10-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-10-15">Class A ordinary share, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-10-15">MLTX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-10-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-10-15">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2023-10-15">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M 4XD=E3F1L%3 7&F-Y"O7'5< U+VAAOLPVYW8?Z1L&E@+@AMGA'?\QL_AKM
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MCLX3]^#4:_]!&#.;'DTBO@(A[^(*=-7N4+YK&)GF!^&E-'"LSB\WG,$<MB_
M\Y64YJ-AS];%7R.]_P!02P,$%     @ %3)05Y^@&_"Q @  X@P   T   !X
M;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV!'KQ
M9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-SS?LD
M:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L.IM-N
M0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ#%V!I
MGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6#\87
M$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#HG%%>
M* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5<D].)3"6T@L-5)](1&,80)"L2_C!9B
M7X2]_:VPI!&/QGWL_&[TH'_OC./WEE>B'_2^FO-CT1=X=-8T\O1!BEHK'O;^
MRPF+-9O\R-%8\>2SP:0<O(%;2AZY=>)P:?EA6;/CO9NFJ:]PSLM_D/.?K7/-
M-;=,7I+VH_\W5_DMC)/Q]%P<T:L#.EL)7(0;^A7N5WGF0/:=D$[H43N*LN3Z
MQ3GUX1W;^PO\*KY?7_**==+M9G!#S_(77HI.Y?.J>ZC+N.HL?X;[:)'-M[#/
M)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1' L#P8 \PG>&%Y_J?]K-#]
M! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7CX9Q
M P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L"]CL
M0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^\?Y@IR1-\SR. !9GD*88
M J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ %3)05Y>*NQS
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M4$L! A0#%     @ %3)05P=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  5,E!7/&I;X^X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M"  5,E!7F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( !4R4%>0#)UZ<P0  "81   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M"  5,E!7GZ ;\+$"  #B#   #0              @ &V#   >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( !4R4%>7BKL<P    !,"   +              "
M 9(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !4R4%>JQ"(6,P$  "("   /
M              "  7L0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  5
M,E!7)!Z;HJT   #X 0  &@              @ ';$0  >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  5,E!799!YDAD!  #/ P  $P
M            @ ' $@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 )
+ #X"   *%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea186779-8k_moonlake.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://moonlaketx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea186779-8k_moonlake.htm">ea186779-8k_moonlake.htm</File>
    <File>mltx-20231015.xsd</File>
    <File>mltx-20231015_lab.xml</File>
    <File>mltx-20231015_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea186779-8k_moonlake.htm": {
   "nsprefix": "MLTX",
   "nsuri": "http://moonlaketx.com/20231015",
   "dts": {
    "inline": {
     "local": [
      "ea186779-8k_moonlake.htm"
     ]
    },
    "schema": {
     "local": [
      "mltx-20231015.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mltx-20231015_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mltx-20231015_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://moonlaketx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2023-10-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea186779-8k_moonlake.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-10-15",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea186779-8k_moonlake.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://moonlaketx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001013762-23-003933-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001013762-23-003933-xbrl.zip
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MQ6YXN:Z>-.M'J2][&:GQR35[TM7Q'?LTJ2:M3J94O^15O>JQX_\!4$L#!!0
M   ( !4R4%=11_L^B"   !>Q   ;    96$Q.#8W-SEE>#DY+3%?;6]O;FQA
M:V4N:'1M[5U94QO)EGXG@O^0UQ-VB)B2D(2PF\6.*S9#-[9I1'=/WY>)5%5*
MRJ:VK@70?9C?/F?)K$6+#1T8F[[R@RV75%DGE[-_Y]3^Z=6'\W?K:_NGQ_TC
M^%?@G_VKLZOSXW?[F_PO?+MIOMX_^'3TNQA<_7Y^_/;%* JS7=%IQYFXTH%*
MQ4=U*RZC0(8.7W#$0"5Z] )NA%LO'GK?G@AD,M;AKL"?MO=$INZRIO3U&"XE
M>CS)7KS;/_GT\:HZ<',D ^U/=[\T-/TVU?]63 F,=/#N^&ZBASI;7]O9:77V
M-P]@!7!X^.?B:TS!56&FDL><PZMPF,9[7Y=JN_!G']Z+P>7AVQ?J;F>GV?G?
M=KO3^B,>OQ#]\ZNW+UY\[46S4WTF.P.GZT,4A>?R6JVOG05!'D;91"4R5GFF
MW53(,(SRT(4QX;(8Y;XO/)G)5&5BE$2!T%DJNKWFK5+7XL/995^XO@ZU*WV1
M)5KZCE!I)H>^3B<Z'-,8'V48#2-ONC_XY>+=JT2-8;'PHTBC4/G1M0[D<'U-
MPJ/%!+;4GXH8'J13O%^&GO#T:*026 @M,^6)"K4P@@__1B%,,Q&GVDNDIT*=
MZ50,\CC.$YGI&RD:IX.-Y\A$L%7V<,T3?]4_.#\6A\?GYQ?]HZ.SC^_?OFB_
MH/\/+OJ']O^_G1U=G;Y]T6FW7[[XJ[-M9E%,,RXN#*,LBP*Z!E1>7=J1;U22
MX5&P2P(WHLC=OSJRO[C57C:!&UO=;1TB:UX=O?O,UX\GC_YKY_6;G5(@U1];
MW<8_\C33H^EC/OR#U' T0@E<9?3:/?]DB9)9 .=*W.IL4N47X44I\(*"%9^*
MGD!N3$7CY]YO&X[P5!"%:988;I&9V'[S4D0C$0,[P&# :.Y$PZW>PZ@YU8/#
MRS?; @8D[N_V'*%#%VA,+:O[P*]P1J[Y!YVN2%0: S&P7(TX <*!6A5Z<00+
MLB&&4Q'!!!Y&1:<M8CBYC5@ER'%RK 0-EV[4-G?SZA+_0B9Y'&;GOUMP+NML
M;\Z+N:A#$$ P?/,K'.&%*G4E!IZ-&+B:/)#]/14#UP/CEESDPJ ZS)&Q(\M\
MBA6S93GXPK G\'D2I:E(44R @D[=*$$"X3X_]X!G'T8.\JKH](C][*-3^,2"
M8:=-ROKL=-!KPN<&D"%C4.1WP/69 J7>:]>$T(9X%7HRG>R)SL/(@ =:L5<(
M-*#%G<"BZ'#DRP >&,'WB0(C(D7K@*0G408<X, 7(U^Y&0HMY CXOY>[:$8\
MF! Y3,%22G%1P\C+?96RQ9* Q">9F(<@LM.59%I)IN]9,ET"AZ8/% 8CD$5!
M[*M,H7BR=CA<KO%@E2L*9A&-_D?DO(V%S/(P.AI'5SR4E4B>&*H,!&!8"$1\
M2+>WXL$5#W[//'AHW.B''?_2,@![/TQ]MODCD41#(%'H #3PC0I(28*^FBCI
M@RI,%/_PSQSFDTV1:WT]4L!,YS^?@0>17NL'ZL(8>%@T/EX.MMIP/W)<JOQ1
M,U%QE."3@/?1C0$O/8!I!F",>#HEVZ5Q\?ZL.5@9[ROV_*[9\R_[\."H@W)S
M1.Q+5PTC029Y$VWI%!FUZM-WNNU@C#S2[<$'8*,4=)COX[_Q1":!=.&'H<+
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MV4W:^N%E@0@OL)S507JS8[!4 1?/#,,"! UM-N$=([K _L+9$N;+A:'&'%9
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MU_!SUU<RH<Q6XZ(_.&,@DDF1YJ1A7,J><EILQ,'N5:;RFYQ"V& W3Q(&K!,
M;JBX7$OZN<SL ;1N=>5\;;_NM;MPOASQRJ<(1/_R_2<3C'#FDRL&T<GG"GL4
MR22;)!0:P>_9>Z\ V9N,9$?^ .=;%*<&^WLB>D5\1(=]2+@=6\;T[+;B;W*"
MPBB##<BXH^N-T5V(&,*S$TX%<CAKL=46/5EO^"93?AQZZ?J:J;=_EG&:YQUE
MVD>:Y^G^3/YN:Y6JNV>J;NL_.E7W=V*\K_&6G'MD\I[CM)ZW+.P/P9I#],?B
ME[$\UVD]XTVI)SGGTI3L'(*][2G".W.FRR0OC;]7Y"PYPL%].80&MP)+P30Z
MAC!XFBL8!+Q'[J;?PNHN(%"/X%I*74RE#BE/6$F( D7X"%,%Y@AP3DV/"TEE
M@0RZ2H)8(VQLG(#3P,G<80XBV[U.&7A+B"\'O,]*G2G^J@2E5RKI=+5GB"OM
MM*B2[ N38KRG*Y,$XRJ4T"P*2:AI1RK:K?:V,<=ZK<Y+&^DS92QQ%.>^Y.2U
M0?DF2A'YJ<"BN_6UD0HD54'1@/P2EU#0-9ALB-6YY2I%+KAW:>DU20]F,HDB
MGC[LP(3SE#;''*JQ)$?-PL+"V9H<Q_AK_#HF6%J@:J@]@JDA(8QJ]XI4.YR2
MXH"DM"2<<:Z\&Z82DE((LZ?61U%1?\"0MV8%\];$R!?WD:EM%LWE6L%A3?0-
M=T4AMU+"E,<J5!C/@&N8^>:.+5R4Z?'3L?88P:XCF'B45,N2\%XLD'"$J\<R
MP1H D098-S&FTX:%*3!X-EWY-T^N2NJ!U"<4P4_4PN1Q"Q\J(>?&ATY[9[MY
M.FAVVYT-EO8LA9Q:P-&+<A!VS:$/;ORB\*,9#AC6!HV60N!M!=&]FY@!=WE8
MD<=I-(R.NWDF0T6%&(Z%PM>0KR3A%@>?%@4]EX%^67CSU!+E)KE&4=O=ZE4:
M#15E&%(']?G?1N5[Z0B$/]>QM#%3+;YA6F(5C<!Y?;G6M5(A15 =,Y]$T1-<
MTH!,\%PK"","32,%T]:@; =!I9'8,5/'LE;$NMQ&^T*'!03%C*A&CZ3Q*_"K
MWFQ7WJ)#FQ9EF*[@$EZCB.?J?+&P=P,K9');@Q-67FI4OEX'R^1FJGH%WT0O
M,L"%0B1P4==5[BO%.\M(9[695JI0:557,G50V5B-P-'*"/63*3E=4 =,2[+=
MYBY07.'.R1]+#,[B#-WMD/07D+1TT0>FHE4,7+("!E/@B8!K?3><^]$C:PBX
M<RRP_=DH][/04W>FW-9L#Z':<:17OMK;=BHY2/L8PM@O>DZ&_=G23&Q57Y]4
MGSJS.LS_8Q[ Q.@XL6TY0,2"K?6U+'[!3RFJ7=ZSN=2G- FR/M$RN*8R3"P5
MOGC?+_^[T1(GI@.#IS*I_93A8)54Z6X]5WI[>]NR*#0Z+&EK'-ULNEEW$VL3
M-BD"OM7M]MYLK73^$^M\)K\2A%XI_?N%ZEGC;QB\IPYOP''18RMZ_J_7%M='
M8-;GZ)5A=>SGU;2ID#2E:^RG_'IZ"NH.B]NP@A(D*R>6L'TO0RY'OKI#WPG;
MH4Y=D .@B!.4A-2&,0$'X3=2JJA >9Q:P226[=L^"0++9(K2G?$$'2(L**)R
MF;DR&8-U'4YM)8V1XNMK_-/-OF-NVCQQ*O=MGH F#XBR/J::$H\BI D5UR&!
MA@QX)BV<+>)QT(TH'6;; $:%(.LFUE:IO^(V$^!"L*504X?* X]O)66^>7J4
M,Z/5S#P>T[(S$&H)UL0+>OQR#RNK0^T/,&=:_N B[9==.KG/5S9CM&-7+VP!
M.FOG.7. ]2^8;&RO;8#I9@'2VKYB&7UZ4-\Y:W^W>/-4 <8V;</XB63B%#?D
M9F7J'83-XF!K .RO5AA02UNL%=\LJ"5$Z(1I-TJXB5H[MBI*=\4RWPK7POOR
M  A+B6#!FOKI?3$K8B%DI=:Z87WMBZ"5^6J#QEFA&Z-DN<W)MKAHHP?2<8!]
M+6:F#SX*/<):[:!ER,#>:6^:UQ$^QMRH40'&IA**]=';H,"XIX$\IZ@UK341
M6%^KO4Q&65_2[(6#GD\.=C-YFXT+&<?B)U"-F-WW6^(<83U9"]FKLR>V=M[L
M=K9?]YJ=;7#\6L_T]#Y3LL]"ZA.%85VM; ?@3LD_?^U\U:VM@I?1YPFYJ;/Q
MO_$-OF$$WJ1?A.BQ_F>#?5T;I*'3B>"=2F\F.(C->LW3-*,6-!P)<"<J,/]M
M#&X46I'BJ"5^%/V ^F86/BR>PL[.W@^=W<[.:Q-1[[:W-EKK:X=69SM%3 N;
MW50@3$4A=QV*5$4V.8(#9!>#/D;($.?DE3@G^KA1B1$'F/G XBJ)G18X*'Q#
MFJA=[@7&GXV]T"CU%JS+D7)%I^<@8W6?K#7^]].$N;?"/-P3\]!;81Z>NS*P
MJ( OXQ/^%NS_%7(^GWEMS"H6M'3][*J!,3K_MAV=+GR1CFD11S^2OK#OTLE#
M/W*O2S_.5KG68QJH?<,(.V#.QIH^'UD:X0L;[]72Q.$6;S>FP2=,MNQ%4NT_
M4C>;300H7=!,Y:_'A[@RFA+/-00!)QS<F6Y-]#(B-@<6]VJQUGL@_T P;0B.
M__H:UF8[%9MC><<:;)"YP+ZQ[UTJ,_(&1D 6C/9]NH1&FBD4CQ+?N]6>LN2
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M,# Q+FIP9Z5X=U 3;;QN$!'ITJM$102DB?26J"@("!&47B(BT@0^I 4)B8B
MU"@**%6D@Q"07DRD*RB1+B E04":) IA)>WDN_?.N3-W[A]GSMF=G=F=?>>=
M]_GM;Y_RLKZQED#'K,PMS4$<'!R@6^P3Q)H#F?W[]#\Z_IWD?SH'!^L#2/@H
M2 _4Q\EQ"G1(F(-3F(/5!P*#0!Q<_WL Z/\<'(<X#W,=X3[*P\O''M!\#'2(
M@Y/ST&%.+J[#A]EO8]GO08>%N41.:ET\(FKGQ7TJ5.Q\W+/BHPJ7&KK%[4?)
MI[5OWW_$PRLA*24MHWA&25GEK(ZNGKZ!H9'9Y2OF%E<MK6[<='!T<G9Q];[C
M<]?7SS\@+#PB,@H1_2#^<4)BTI/DE,SG+[*R<UZ^RGU34EI67E%95?VNL:FY
MI;6MO:.GMZ]_8/#CIZ&Q\8G)J>EO,[-$TO*/E=6UG^L;E-]_=O>H^\#?@W]Q
M<8 X_Q/Z_Q>7,!O7H<.'.0]S_XN+XU#4OP.$#W.=U#HB<M&.VRM4]-3YN*-B
MEYX5-W3S*&C;D\5OWQ_EE3BM0U2D_ OM?R'[KP%[]-]"]I_ _B^N61 _)P?[
MXW$*@Z @)HTYD1<5].RAAN#';P6CC:J5\*X^<86S1Y4>6F+76" F;S(+Q,V!
M^H(GP^;='("+2V[*>#_H;$"/H0VA=U[4O:F>C'[TRTMII %()=%$PSO,&WG3
M+(E!YX>=*28^67G6%ZRF#=E3'&:!NF_LH;^!EXXDDQN7IMIR?;=-*0<"OC!R
M7=6]48\%NAX04U+;Y:D,Q"F67"W3E<9J;(?#^4G22QV3IY_.6_L?S_.80^<I
MKC!+T#&QZ.H U^P:="T\0&:@HBH@IW%C>A:'KU[:D,GNC K'1M?"^]N>3I^_
M@CB/)MTS*OJ)/TSGJQV4NN8D3.'$6B?!3<YOB%5;<SVIU2F1C[XM=M;V>MJ+
MV90*^<B]G--.^FM(GX'ATU6,G.S?,-U]MUI'X=I+*IM#ZX;*"TZN?SI='5VU
MJ;W+TW0Y* O$Y0 0:^;G_='RVS@N(!*]YRD$*!'3P;W4J>^W_J)4I[;W=N3"
MUED@'M#QS1\87G2W"WJI',4_:8LM9<[#F[[L?6V1N&AB2;'N8ZJ.0T8,A1CI
M)(9%7W;/K5[#/T^.1]W%N0.J-"@RG%%J8LOD![C(223P %BT5^ZY^SI<J$NS
M"O%\ZYC%/8V$J:K*;V9GGI7,6$K/2137!$@X"B@-!=]$3NYS]V&!4Q5T<7TB
M-$&!4I0*]19*R7%5G<UK'^\^#\!(GHU>,@]=(J""2".*4DH$P^C*80G)W'MG
MC=^C'6!J9.^D:K42K:2C/H%9BOR.G)K]TZ$SGF7FU9^,77^OOB^L_4Y_5ZZ4
MTE!/92YJA>,[C89O%CEO+[9^9%QG8-!+Z]@Y/F)D62D"36TG5SQF@?QAH"86
MZ.XDW?J-OZM3[V**HXS?>I2O1$Z0Y".D955P-T)77=LLX>$)3XTP^!P+M!5#
MN\_\LM@:TF,ME 9O],5L=?D0V]/?M[27VOQP1K1VY_958B'QRV AW<]_?G84
MO%++O'JG?6R'/S@\W=H^^7(2'57W]M>69DCX,,WZ/?3&>%UAK]UXA*QQ+?3Z
M>+,J_"^O?T=6UI;>ODP$]2G*;3,&V'[U$7I+OS>7YL3D^4.+IM]F@1XAF&/R
MTL .N='A?==8>4?+.$H5.+3Q^\HHY R@GA%Q7-8]P<IM/B"4C#2M,=&;E@=[
MT2K:L2-=E@>F=^0LLQDQ#XF)W6L/N@20 C[\G<F>6$8.MU2'U)E%UPC7Z854
M5VP)$6<TL!2*MB/4D7>N/$!FB1]TY/]^_ML64@#;VQ$\2C#5'H&T;4[%G3 D
M)II>D%_ [2T7<>",Z$:,4H@@71=8(Y<X!441U_KAO.LH#7)BM;UB9JRQ?8NH
M:=F6X[1DJ%N J\_0O']N67VAWW:SJNQ'A4+$LDO97L/]3FN]J_S7'^*\!*4.
M)7A_C](TKN=]R#,?E\L4K))I\G44+S[K<&[$KM]K!;S0$]H1ZC]KYS]@6?Z<
M?:<S2GNA*/.4VK1:H!]HM3&%BF)V#;LL&T"OA?VU/T*X@#[)U"T2V+)/%&YA
M%,MJO;-\D<79>^)JP0_AD=*7WU_;GWI:\/JD__*K##.UE&]/$Y2=LRSF.G\L
M@$+_F//P?TBK6QJJ%@S&-%=9A:_<G5>!%T2[?FIAFEF.0,;R2>O[CE&[TS[3
M3!DJ_T/^[>!8;A;(,WTY>$N^;5!Z;V]P\^;LSUMI6CU)4KPKX^E;C_0BGP^K
M51,OGGQU3G!%W?OSK5<[NU*#%^<H!_9=$^+^EZXGJ<^K6.PGS^],0E6A7\X\
MMZ-FA.;+C^C-3>JC[1\HOWE[*$7Y]6%^H6M,G=ZS&<5X$'2@(/WU]L$?P->0
M>G!3_K[$7-.1#0Z?[T/F9@D"^."MBK.R"*C&=RW[S-0QT5SF#LS^I&[(@B[:
M ;S9<#=%N=QY?FF7'RW$?"^+GPD9RL6V[;FCBU#-X%D.4(+)XQW9@JVK?A2Y
M##.SASX&WSA5+)"0F;2_Q.V3T@:[H]O[(FMBV^$X=.VPF-T5NXM7Q*YS_[W&
MYMG[4+^@&]04=L\6,2>,O@Q4'B0EX<01!2A.0&_6N*JT=91N2FZ9NS'6'&CM
MF 4-/]A/6Z-(-+]]:JE2U3.(I&I=@!QC9*-]L3+,*7B314_(S!QQMA$H(1'2
M=L$\9]Y*!.5",.&CK:E=5Q -W6'J748VKXKLVG+Y8G)2!D8V'"_\K%(J17=?
MK/5I9G2A@V/</IYYY,NH1_L;-_#U_V"NN0"MI.037;?Z/<*IH\3 X:BY5=E;
MF!\"WQEX%NC(+I!G1L;3Q=>H=CC*F1K_TMF-*19(#*GM%8HD+:ABA!&]2_MI
M7= W_C\_GC[$ KE/[BBD7L)P;XM\GU$;F/]Q!\,P37#YIR(>-:VXWV @*.N2
M?:UJME0I&2,PJ!W6?U%1[J:\BE5I,>0J3=? PVP!_GF'*=86_URD*7J?BC;9
MK:Z?;FZ?6PV;="UQFC*RFF6!2O2W@F@B]*.,1#;]ABWA/Q0=]<<='VU*55>)
MV$89(XHI3AA=FJIRK::)W7)0Y)AQS/LPY_>_T]KSAAN2"+D&]]Y<:COXHEXQ
MDUQHR''TY<E75H]/72KN?N;RS7?_S_Q#T(9EU:WV2]U:B?>'*K_(-+[\KO@A
MW:7[J6LF#ODLZ4DPG^S'&;OBN+1([!]N\9?>VG(VUR(U<*?JC$KNYS=H%]CZ
M=WK:IZWL&)_.T<E-L;-+N_T"MGY6"@F1?]1[H]CZ6UFPRZ7S0=&?2A?G)XL^
M5M#E4EF@PZ^!((KDDB_[-@0=#Y%L(%<,8!,<A0/P4KL$@9DS>:5T1R!(HR;(
MJS+@@%KDS=] (.T<-4/H(NB7/H6H,[-\JFQBU$)"N+J*/KRVMX,K"'V5?Q]*
M8(&<<]D?! V<A::8F"ZQ0( 2>+OY+9"],0<;76;DH'3\Q@B(HLX81E2W##ZI
MR>VRD\>X>X#,:HU/^7I#C[Q;^J5?,^K/AD6@'V?G'B?#,_/E!(]21\ZC.0Z<
M]M&C:,CGL& 1PKNTB&ON&U\)ZROM1XQJ73,1_";$+\I> 3:?QBKS.BKSD.\<
MTS-]B85G?( 'TLV&7MZV>2]NEHEE8X*SIR\O%N8YLT 7T( .C9HXB3N!^@B5
M@?K6>MMUX-H!+HJW[012XW3;D#^3#\@KJ<,RGHOYO-H."C()+4;,.GNE:"K0
M])CSF;"FYO[FUEUQ6C1 Z,<+0MGZ,)LZB#M*$6"!$KJ\B$)Q:-$N&V*1B+_Q
MD6(B(\2,G%T<ZUWE7+*=$9@7TXF&*&@/)BFLWL@&#X'ITGO^*A/HD.&5IJ=S
MW\UHNM_4OPD^M52O!'Y._^[[? 3YR3<<]L)J0/E:E=P]+'P"3Q?#<C-Y:+0[
MA<O48. K]/? E U:']'YXA:Y4(\B*)]VJ](;@4FJC_CY-4!,G)] .^1<9I7O
MI'XV,SI#-3.T\U&!SHMVD9R?^5I.HBE$YZE:O8W*B2G]C*'UV9VZSOV_J"AT
MMP ^$(-A_W4FG!19:@"CWB0TC *FI@/ZON0_)-0KBM#-S($Y5Z"$K$2-)Y=5
M].$3F:JY ].PL6>)"9"**H3&>G&BF[7+;G.#]4Q_AS;S*6H1W!R,H4DR/^&E
MT7X>]E.Q,#MR2.*/^&[YX\WW@[M@%/U^28E" <"7:*WL=2:PFR0DN=&!A+CS
M[A\2@OAM+UP=TP;B*.J^# Q=B=W *#:[O0%BW^[B>?W@;'/INSC#27W?IUU6
M6$&#T&^1+1*?=S-U)[FZK!JAO4(I-D$D8^O:2S'>_HQVC<),Z\"3=GN^V["8
M:-H_;,*$X>_"OVV:Y\;@X^ -09A$%B@8-NNZ.K2J4+P)/2:W\93YN4AH[ZI7
MYB_UJWK%(@#C;7#M5FV>=;/^5_?YJR<> KJ_T_2\^UZZ_[;*/^_\== WNE;M
MU$&+C!1_XEOOO)5=;R[ET?Z[(A5Q&8+AX^'P8U^I.ANQKH2.] >[Y[<\!?/9
MW5-1[K9M2OV;T[;A@?7WC?R5-=;HU\_&*$B_P<#2(]C_TIQF-[JEHA\K@F3S
M)]F7^O(=67&2\(18WY33,UQ-EP,B2._=>CK<C1P2'HYO-V%%-W/+2GI%AL6[
MJ-.WM=,S/QVH4Z:9O"&T0\S/"QI0(9PQ<PK*!9$!5NRG8HJX-W%Z8Z<ID%?^
M4?^HG\!/FT#+"94!S./U@<6GA6*P,^LM7U^61O_(4!31)T;U[F!P6HQ<R!%T
M]Q!4G@[Z)(E!B3,GB\1T=_ALPE:;<9@ZS"-Y[O'MYNA71]:]QA8H79<WA*E=
M <A6WNK%MV R#/H-3/5FVUI-I%9G2!)$&,!0A$A%C[KT*=;+F@.8Y =ZKY;A
M\G17()TB:M9(<4HU\2"AQ1$53!'9+Y<\PARF-.M.C.\R+)L$C+Z99T?J;9FT
M!Z;41YMH(WL-!V]2#8[BP!E@3>*"2YG)8*)!C-Z 3== MGS^R>T_,ALIX5AN
M@QZ3B?4PV]_3R0<9\,1B%W.'YQ&%BD:_F^?;0Y3;6F?TFL;#4>ET0Z"7/+C,
M';^+?@+E[0HE%CW!<4TO)2Z;4]#QNN\U^R#')TK:6E-6A7UJ_'.B)*+L.VQ$
M\A"*F21I#^]"Y9=QGD(T<^8BM&%M*UTC+Y!FB1H%\S&/!;A^#M1X5HSH[#=R
M:$V.N&I]J1920(R)22T2AKL.KI68;M?EZ#ZSV3[>%R<+?LJ4(F.26*"E0CC9
M^2A.E#ER(.<I!?#1 E'#4$F(,3"X5!@7&%$.\'6C92!'/ ?0Q//D\CS='P=1
MB=,DP;P(1D&57X=@CI=/8+2LM3_?W+NM!79?Z:"&P3RH\TR",+O_+Z(, :=N
M%D@.'8"=4^U#F5!8H RVK=TT'Z??84J2FULS3*X0\0+(<V15( <VM=6E3Q3B
M\'<][^)/=16O>W6D)%9^>#_SR(EHA_-RK1QFD@6D/X:WW[G:?3SK]2[?Q-^>
M%##ZQ?MEUQ5]L>H52I9XYEV1=$OK+!-/#N61WW&3<@-E 00.Z\Q"+4\@>3#W
M<;3[#62&I?'BY95I\RW4,)V;48GVW9F-[\$L8V8VEX4>0LX!MM*Y4SMN9'!R
M>,&#1=A[QUM31K7O:X?A_I)YUS]F'Y35YF<..!!%.#T#E]DRI"RYY4%N@)R%
M]D%G?9=V'DLN)3T)+^)!NLGL9^@(&,% "*SGV)SKJ(D^23D8>RJ7X#JI\W(5
MWU(OW-5SU$?[K5JQVV\TM0V0)?^A2K"KEX3Z@&Z&;7TJ1D01(:VTF\BH!D8F
MU&\G <=7WT(N>HP[AX#UHP0G@^F*R]:8(_X]O9<A2D!@=)D"C!1X7$MSE1:;
M;Y1V]AWLM.=)-IE1&:\@_'0_]L3]Z&XOE!K2GJR1P%ZW./(X,$Q>M@ B)-/N
ML4#$$U]-C#4Q79*GF2>GMNC&-::_$H)(Z;E<+07E0,IQ_>TIHPAFZ5.U>Q\L
M6V23W@U]4QLT*/2R-^#7NR@WDBA>J68QA6]=SK+*<OU>99O[YGM[\5&+O/T6
MR_O61J^R3Y+0[RH[T/#WA2?'W_.Y#&WD1>+/1MIZZ$(CT;[@N6&J&:-NW(T%
M2@Q@O&9*TV]UDK\[[D-.CB&52!Y&(<?\]*)\$FJ9C<3AF7M[VWI#_[RE?%_P
M_SHPI%7PXR2@V8.7Q^DNH+LC(6K,$4FX</-?'-=/%JB>327)KOJ]W(&:P!4U
MDY@JQ.H?ZP[*93W\;:/'4>]F9JSY+N5B7SA\S5G),E%@\CJ0XXE16U]HWNRF
M58<&8!]#1,8A<D@VKL 0 >9(H5$[$.,C%+]%1Y/S2/H)2+@83HX2G/4:]ZH,
MB*=)7I=PDO$9:0R*5=-2ZT9M:3GNQY>"*2*: ZTSRC?9U0^F:SPAG7D:S!9Q
M#);PZ&NR\ 78BQR?87+GN]*])01:L-XE,=!<N]#C1D);DM:PLF-^ ,DK=3B,
M"1Y6L6WV&Q"N%4_Z''K^A;?M"[GOOE\D;556X+(:$;8E*95 G,^G*P:+?(I?
MN +Q"SIC$;*=Z#O,N%F*>(F\^UO%^891NZ=9"GZG(18O2S\^3G^C$QEYH1P/
M19U!=SM EPJ*CC 5W.FG@3R:-_T(.:3/6%H'T-44V(28C@:MC 4WNZ2W%/G4
M!D!B_ [4]_J_ZBW>GF3GV\J[A]W[>>F32V"R6PBF2!C%R:X;!*6XL<BW=SRF
MI] 0*%X62ECD:"* ?THWOF?7CA(S^  :WXR7>=LX'-SBY(IZ%EKMXM=8L-$Q
M4%.<O-+<W-;^OO% F_JO_#Y ?2QJQ'0'@9>2'N(XD08048QY2F_?] $+%!\>
M(HR()VF4-G1SL4#)R!!L0&1.1\43Y$5L!^'MIZKO@>JFZ;LIU'4QK9>BJ_?I
M$H+2'OQSNBY]ZZN32C"U'N(_?V-EVIRNV#LLZ#FHVMK89_EI6)J?#YJ?L'-]
M\#(7:%^6]XCO-8IX$;UPIO%&R=!<JUJX?9#&P>GYNEB5U_1(P(Q4).V&-"3C
M^^"\B*1!2;R03E&JH[S<:$2JJ2W-#O"IV_CC)Z.?T<0"-7S2D<1)3T3D1>_.
MF3HN^+:T=S[R*X[R*PI9P="%-9?W!Z"SW%04HPQI0R&0S-LI2GT044;'O]L8
MB0ORDW1+1A'UB_8'B-CS[L 2A./1+?5[ZMD$"YH/Z<N9K]3STO:W'EI5_29L
M6=+. 6 J.Y\](J'&BOA0$@'3 N1WRU0.,CH5(D\W"O*F><XM92>3"+/GV25T
M >"OG3_ICG06 WI@.:44>@0Q7>,7V9\I44\IU3,RV>^(;OW- LFC;Q%2H,=0
M)X"2?C@9%B)&=YQ$W\'//*=F,#JA@?/P/KALN$]G4A\+U%2.]ZX$) ;6J#>!
MZ&6,8C@Z :(RO2T6,(M-"=95A0DCEJT[4P0D>M9NM.?90N$)1&63&NU$F6J'
M^C8-B9'U$:S:(O6NC_RI0E6>3^([I!_U4IX60B@1!YFT8B5EA.A(;.KPI/,?
MAC]%LNGZN\YA5^<[>9T)M;3!*$(,S@.SW4K,V=8E*RV;)Y'^S7-*0,72XA-/
M*;+0DP@"+V*X;T%L6F<;W@L!4\")YL@KI0N([-G(KSYMH[(_)DH;)X)K@TJ'
M3 ?,O%<%N)F\@VS:)%(L^A XD9_@EI /-K#!5IE6*E<+AANC$Q<85<L"?3TU
MWB=B#4[\U:QY$-8Z^:.-!2J/^"O+ G$]Q/2B>=3P2P5H,DPS =VXTP\607V&
M2G9%D?J!8AJ4^2521BB);DEQ(^*[BWCZZ_RAW-LF%TD"89=:<&-[F[V,=HK$
ML!-%(J<&@;W4U-DU28?Y(%9E<8/]BS)TGF5L?"N^<?7?,,L"H6:TD=(3.G[T
M\TCQ"KH (U<G5NG"U^"3QYH.! J*^N:.C._Q>9[.VM+(N>X"1>3F9TJ$K2VU
MP3E3/OA(OUW+G^ZAB)6^.S T-WZT!N>TS<_2=Y)E-&"Z*PAVMO^D9<D$/*]X
MT#7^;H<Y\;8!TM_A;Q&^/O3+0R'\5X>Z?=0NM+1M9PPQ%H@X4RAMYZE2HL=T
M?_)!/%SSGX1G<4-MLJ?=3>Y1WG6* \7L:L9,H@-AO,R/^T6":#]8W*)<N.IB
M(E@:=0:A2>0!R$PYJ%@($\17J]FWR*M T24!-79&;YFBHUV6^KUMS?X:I3G7
M4[M30S4\7KW$*D@^@PFE]%U/5.)S%*L>R3]K(1MO%9JZ?^?YVX6J.JS;3+-W
MN>'C_!NAF4%GIAL?0-N8QOBE'T4S^DZ, OQ2B;P!T"SPN)=(V'8KO4@QZ\U]
M'/JBG@5ZW&LUKH,50FSVTJ9T$H++,@?&/1_-3KFU!X=O/Z"N7A28"'-56EI[
M; (G@4% 1:^G(3FR)IJ(E4+H][ERIW:IU_EGGNL8I5]\'1 I4UX0%:3B]SWV
MD9MXXMSAD.3Y.S</I[ #+!I06:2+5A#7Z&*I5#A%LUM3_),WD>V-UI_C4YC\
M2'.],BSN./)B?4M8>8"*3NCW[RV8JFO3,KY/U(M3@F:OT-^9^8>&>0>R^RQ[
M>MN,=A89R<B : 7B.:%^<(X-W&'*5'J4D7/JQS-!0OVSNNTGZ6Y+7Q"]QQ/Q
M1#U.K4UA$^N/ B+'AJ"M= X*]YEE>=&>?^X&I90D$.YO\0W73X;>?^QWLSO6
MC*9N%5ZAX3I^4/+CQ8KRD'BMO5W7ZS* (/NC[6V)$8)^G#?K7)86?E9@W*8Y
MN<L'=2?K=>Z[A%RK@SD'YB,H^1H8,-"FNC!JZ4+$Q:.H,4\H.63K+^V:7\>]
MR,*SXR9!E3, G+B?\2MHZ@13!T OR]+:PHV/*SCZI6[(@R?KPM>W5^^?H%V6
M-J-94O2I(XP7$ &$Z^( 7@SMAXE'\9#?_\*<P9<'=*SU8;CGREM+^LIR:;TM
MJ6\MT23G)U+I2&A@E:7VL0:%!A#;:IKV!9"$U<[?L0VYG;%RZEGY>Q:HL'YN
MWL7=M3M8F\UQR?=.#;J35:1!-Q-\KK0DMYZ^;_F/PG/L00]&.!"U>#MW:D.P
M:SJ^@"'1%G;N\TKRL$'-N8^_L_^^"(V&3\L95T[E- 9HOO'_O1MI*9\![E>[
M[.\F?4D0C_A*]=^FBI6M S^IS$+T4B>:[)[.3?U9CZ'>9&273HA2?<;H9J6;
MGEI #MH?3?SBM Q.T5'!31/G%2Z-8VNWL>&$)*;,9-J#[Y*2H]V5FS()"2F+
M_N<N%R\S;Y7R=B8_NZZ<O]+*[G FY&%0V<V++)#Z\:&!,%KK@Z;R&1>7KLI\
MMVUM48-,OPY&">%]>YN;Y#+C9@_/@,6O]B_HBVCR93QP"M\'GL.3T E,;>0]
M,NX]$?IMN=LH*[NV,N#!=L&O9/V!+Y<^!->3,8_5L?>6@Z*Z<U/H"Z<IZF_)
M<WU6_0$A/IDZ(=-57@#T _-0 O]=C0P7:Z&,Z.HR^V:38%\WF3=U\R'S#M45
MG\JXCIJ]JJPR5S&@IY6]HF2$R9E:.4#JY]]W>9T-O]WY2<-/,?;]ZGZL&@M4
MB0'THJ@V4VA?34 )ET<!#\C8K+Y:ALZB^],I#T@"YN)-$Z+$75>/HB24U-]Z
MFQ7K(/]8XIPAW3-['*RK2!%\/80Y_1"Z-;B=2J[HA\KA?:"SX*7%1W/78%+(
MZP"4PO>!*1MT=\/-5%T7+88(NSZZ^[=9M<;-C987<[2N;CFF/6BK;BU#+(RK
MM@_G#MN5R"EV]IMR- K.\ZGXYC\;D566D)58X"]>6U!0EJ;J[^/M&\A;JI<M
M$_NH-KV@Z:J"V_T; 5P<+?S!D@5IG (IDO[I1L?>ZHO$[%Z/=G_(A<YK7Q3U
MUOZEUA=J&JVR3)'.$-+)SY>LSU#00("K!G2BVV.S=+.)#E?#7&NK/>VHF)P#
M!8WARI5O4BL3RXJ):>[V+[YON"R^ZDA7B@U'5B]4].CA&U9S*$),GA4VBWPK
M6@XJS*IRWF"!&I42(;R(@XW1TJ[FQJG=G</K'5P+G:^;)PO>CG0(MOK-KB7\
MJE-_^^LSU>A>CMYL>.&]4.0DFZ?C_[5>=%M&(DH V-BD)E%:LBAFU +@"VGS
MN!/)HL]:W9P%<M*'2  QKUT1G$L[B>I[ZA;68]A@=;KNDOK9$3? I_F15 3C
MAO-5^5\+JC&THF_>TH92O'P"?2*KESEEG>L/^Q9+WP)MCJA<$AYP\CM\MOHE
M&;W W_< ^3I6R*K'< 0B[:FOG+:N)N^5VK.LBO4&!U<DO"BM',42"!8\R<_?
M4-J<!VY28%QQ$7*>$H+AO[=4^XA:03>I;<IM7QD_VM4F\=&PG.R2K1^3N$W4
M!782)</P(@BK'2;O,R)L5A-&1J>@)%#ST*:U#)/H8D2,S0165UH3(@[T$K&)
M)CR*2<D2FQ;U$O(G9]YX6%&G,C<<S]6X6<M7G"[W6R(+)4!YV'&Y 5Z?$0_>
MVB?#>O"-A.U^FBG":CX<^M!3%^BD>/=!#S-UD!"R1R7.")H(.?/=;(D@Z5=T
MS*F7^MOYYT%PV=U<]1^Y06U_]*34MS?WMRY'B@?E5Z6W!*==3;A*&/YS^4/#
MP(#WAY.)%R[[<>[P"UM[:R1+^^[Q9PZ>C9NK\<4.>SBT/3\WX-3G]$7%YR]A
MRCMGH%9NCL-"/ D]\U+NB-OC?+_QFD?7<WM\VEPC[E30IJ5'[-+*_SI1[XK?
M[)W$M#PF3]]L5[4Z2X@PJ)P-_/2-GLY(A7K!,W!@8)D=#.?0U#4@?@F3#&W&
M]X5P^;- _'1=(CY)3R8KIP<V\V=II6!H0[^0 X@5K$]%UVP4GIKXD-,'.8<?
MW]VVHBH*F]BO(DK_;O:@W\'I8KY,GAD26@X11>4=1[&U /]./X,>2PJ1!VY0
M$0!AV2:**)D. 04P]:9^(:U)IJH?4";CX3 1_US\(\&&J%#%I,0(53[EVN(L
MZA?.JP/PQ7A94.1?Q-F;K^%J!@-'UN2]0:_S;\DW32>\O'5NKC[QR6.?K(/X
MTYF#JEE+_$N%:Y&@*K;NAOY"%#Y \+:YNWXP;W%QXK2-]M5P)>_P2'F9-OG
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MX._  >6=!.A21:$ZHP/OS383GR%0\GX:"W07?!1Y&/\58HB@#<B+=[3F7*!
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M-ZY;XYNQ.KM*]2DXW1Q%6@0TP<ET"$J.!>K!,!)Q$@B,_1,_??9*&!4#BS)
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MDY>.L&50D24CR<'\?27;,A<# =KR).^><W;7NRO3ODI" MX1%YC1CN56JA9
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MACUA"LK!MXU V\G4U/$/4$L#!!0    ( !4R4%?)U'6G_0H  ("&   5
M;6QT>"TR,#(S,3 Q-5]L86(N>&ULS9U=;^.X%8;O"_0_<-V;%AC'B8,62'9F
M%QE/LC VFV1CSVS;1;&@)<810I,!)2?VOR\IB;)$\4A*BI*<BQF/^![JI?B8
MI+Z./_ZXVU#T0D2:</9I=')T/$*$13Q.V/K3Z.MB?+&8S><CE&:8Q9AR1CZ-
M&!_]^,.?_X3DGX_?C<?H*B$T/D=?>#2>LP?^/;K!&W*.?B*,")QQ\3WZANE6
M;>%7"24"S?CFF9*,R()BQ^?H[T?38XS&XP'U?B,LYN+K_;RJ]S'+GM/SR>3U
M]?6(\1?\RL53>A3QS; *%QG.MFE5V_'NN/Q3A'^D"7LZ5W^M<$J0/%XL/=^E
MR:>1VF^YV]?3(R[6D^GQ\<GDG[]<+Z)'LL'CA*GC%I&1CE*UV.).SL[.)GFI
MEK:4NY6@>A^G$VVGJEF6)AWZFI,T.4]S>]<\PEG>[;V[0:!"_6^L96.U:7PR
M'9^>'.W2>*0/?GX$!:?DGCR@O)GGV?Y9HI0FBH11N>U1D >[&2K$1,5/&%GC
MC,1J1V=J1R?_4#OZ2[GY&J\('2&EE'R [3IKU%4&35R;O2,BX?$E>Y]K,]J3
M??G=$=G_T(!ZO/,F+'F&Z;O,UR.=V[XA[SOBASCW1UJ.\^1]1[H6^7^QG;4M
MO_GPVH\K51NOY:>&1;++Y 1&8FU25=$Q N=[R">&LNZJ=AXUZJ5J-.>BW78U
M,^9UIB0Z6O.724P26??T5'T8JP]YL^5__IAQN1*X6*69P%&F:\J;\6ED*9^8
MEI3R0FA?6$0]C2L5DXC+J>DY&]/B,!;A#X)OK+LM6\TMA7_0515?'!:Y"\!H
M0R9(RK<B(F_JE;I;Z"B5CC94*M22BK#QU\7HAUR#?M>J_WR<'&IQT-%R";3=
M$)8M98V6%C2+776SS93NY7I9$)UL,63VL98@I7'<P1=RQ[':^17%:XM]H]Q5
M%UMMZ3YN% ;1R39'9B]7&J1$OKKY"TDCD3RKY7Q7.QHRYYUN,=GJ^YHF+ 3:
MQF 2:EI/ _L]62=J:E$6U/DM41L[AC% [WKH[[1MS@56<1#0#'$(SA;U(%1%
M>>+H@K$MIO?DF8LN?)HRU]383)JPU#5!,6(Q!J)1:%$A]D3$KUMYQDX$W?="
MT5*ZY@*P:J)AR(*BP^X-!*22^V5D*3!+$S6 ]4+2ECH_W0#,MDX]#%U0G #F
MX%.22N^7E,4CH53=#\"L?T"QB5W3 ALV>6DK@R(&M <RDT>@,B0<;"Y?U.I<
M+I,&-K:F]PE/RW87/Y4X6(1,AP,IRL.0BO-$4NTV1 ]#+:5K>@"K)C>&+"AB
M[-Y 5@HYRO7^(;ED\2!$*IT?0 R;=CQ*48!P-)WUH2'5/L&X2M((T\++E=R6
M=C3/HG4-"&C7A*0E# H4R!T(2Q&@F<E#O +S+X+%,%QJ2C^PM*S:4:ED 8)B
M>NO#1.F]0#+;"M%P#<\XL-393=D>L]7]64 7!"@]YEIW;0MY Q1/,] ERY)L
MKYZGN]EN5D18&M>6N&(#,J>9,,N#8 $P93)0R)#2H4+HI>?U70*6J8<8P>:8
M,K<$V$TV*6AJ B+!:@R@X:#-GRGU0L1,CDP"TSF+R>YGL@?;U=*Y90*PV83"
M$ 5$A=T9@$4I1KD:2;D7,.Y$LL%BOTBBGJFB+72+!F2TR8:I"@@.P!I 1ZE&
MB_G,YTRRQ+MY+$%-'I+B>? >2D"]6UAZ;#>9 <0!H=/M$"!(!J%FE$^0YBSB
MXIG7'G>8\:T< /<S'L,KE)XHMU -:D(3K<Z0@  ;XA/ K!'ZH7@F!7'U'D]>
M 5(U>"'N(H[E@4K+?ZX31D[ ]ENU;NGJL-MDRB(,B"38'<!/J?R@/R 5@VY9
M*-!,W]#4J7]HID.AF08-S?0]T"Q?>2#0G+ZAJ:?^H3D="LUIT-"<O@L:V?%>
MQYJ9_'@KEOS5]G VJ/2"3-NJ%9B#+#Q<6M[Z8%$!:CVC0GQBDB^L;L6=X"\)
MB^ E,R3W @Q@VDJ-H0T/';O!/GZJ!;&.\SK6%(ORWB^)EOD999HF[4-,H0D/
MDJ:QWL&E4/M$XHZG&:;_3IX[3\3M8B]X6 U;(6DHPT/%9J\/F"(&R2 ?)]8E
MKNJ&AO55,J/<W2O %EN'5X!KA4% 8'/4?@6XN'I2B%QWLV)4$ R,",UB9YUL
M,57U<:TLC"YN&VKU</Z]EAH?7V25W87>/7(&/R#0EKCJ:<B<[FVS/(@>!TR9
MO9[+4*[S=#5>99A([<-WK<S9S&[:J29R71!$[YIN6M.T+G?<F[^)))-[GO'-
M9LO*NSRVYP8!G:M>[K2I>]PJ"J+WNYR9))1:U!0[QF+!:1(E6<+6O\B33Y%@
M6ZML(E= P 8U#6U%$"B MDP.#D*DE8XAN!-$04AD1^0O :K$0N+VX<$ZVW>)
M74'1;UC# 2N#@*37G@F+#!A'M0A4A* \QB\V\S3=$O$F>"PAGA "S0,@M?0A
MX@29[(6J"/3)UH)$6SD_[D^FJV624=O)95OB;$X"S%4SDE$>!!N *9.%O SQ
M!W0R_>OJ;TA'.>[^&[X46"6/7>PW*TZ![%-6E2L(.BQJ#BR2(%" ?9DTW'!4
M2E&A]9&=JF'6TARCW!4 5ENZZQN%072ZS5'KR]_H:T]#_N4N>I2F"/!"@EWF
M>NBWF32'_[HF" 0ZC+5.2DHITEH?+R0<IJQU_R)@[6T1L.Y9!*Q#7 2LARX"
MUMX6 7JW18H0.2[=KFBRQD!RPDZU:R@Z+)M\6*1!H0+[ \>,*@0=8EQGM,Q3
MG*GT_&*3[_]*?K"T$M YRVG99;-*:FD3!<%(E[-66LLBZ5Q-C)3:-1?;.,E(
M7)BY2AAF48)IE1[1=D6\/\09+0/-5^#TZ,-@:)C)%DY%F,YE6 4>4EVZOI1>
M/(#Q&Z'T9\9?V8+@E#,2%]=2;'>*NO5NGYCIL=U\: 80!X'3$(? HS,J:/RD
MHI .*Z^$>2'I&Z=;EF&1OTLN;",3H'-+#F"S28PA"H@4NS. D$J,"K6?%[2+
M[!'5(JOXW2&P@9#<\>O:G::-M[:MVH"8Z30(O<-=YOPXK(V+*$^O6&9$_5Y$
M\D*^X R7WL#V0G+7+U5VF3;?IK1I T*HTR#X_F05HU+%8,V4MY0Q8B:76FO>
M\92XH7*?.*9EL9T[II($A(?-5T<&&8&TU@L+BPVF]/,V31A)X8G(4+EEP6JQ
MR4)#$A +-E\ "[D4::T7%BXW1*SE]/:3X*_98YF?%6P;H';+1J?E)B-6:4"L
M=/D#F-$AJ(C1*77]P+,[)!0OLBS"+;5('6,#FC68:>E" @8RUZ*%DDA=;[GA
M&5IR]#4E*'LDZ++\&;IZ)OBB'E^_-!)%ZH6(8E7.8BQL"'6)G?_J"&BX]=LC
M+640(/7:@W^'I(I .L0Q-;>285$_C\M-S#.R =]VZ ]Q1=!0\YJC/GT0- TT
M:3*5AS5/KO- I")]9C.J)[>'EW@-D>.5L<6@L3"N*8)@!+0%+8OKOQ7@)W?>
M=D63Z(IR#%]E:6@<9\QKVS.2Y1T$ 1'0=@6ER,N%*%=ZZ?_/F#V)[7,6[>\$
MCPA13UFEU6C5=_UM8+1;9M[4I"9-@T(#XNPM?@$"#U6@6AT?:C.6SXMYZJ%Q
ME<V-1T^+1RP/X.TV2]4,*HW!5\$[@QS?7AC0 .,F0T=$0.@-L G=<,@C41[Z
M 17!J!;MZ?PL/60!)/'G_3UY($*]=[ DN^RSW-%3QQG&@%C79V^#FV.>S/4&
M!@'A6]U"IWHIJE> 5NH9L;(*]+NJ!.6UV'Z_O+[I6GZ2F_4F^=<*IT1N^2]0
M2P,$%     @ %3)05PK;FU]7!P  V5<  !4   !M;'1X+3(P,C,Q,#$U7W!R
M92YX;6S-G%USXC84AN\[T__@TFL@D&[;9)/N)&S883:[24-VM^W-CK %:")+
MC"0'^/>5;,SR8<DG-S[)14+,JX_W.;;L8TN^>+=*>?1,E6927+9ZG9-61$4L
M$R9FEZTOX_;5># :M2)MB$@(EX)>MH1LO?OKYY\B^W/Q2[L=#1GER7GT7L;M
MD9C*M]%GDM+SZ ,55!$CU=OH*^&9VR*'C%,5#62ZX-10^T71\'GTIM,_(5&[
M#:CW*Q6)5%\>1MMZY\8L]'FWNUPN.T(^DZ543[H3RQ16X=@0D^EM;2>KD\U/
M4?R",_%T[GY-B*:1Y27T^4JSRY9K=]/L\K0CU:S;/SGI=?_Y=#N.YS0E;28<
MMYBVRE*NEJIRO;.SLV[^;2D]4JXFBI=MG';+[FQKMM^R@'ZG)YJ=Z[Q[MS(F
M)@][;3.15^'^:Y>RMMO4[O7;I[W.2B>M$GY.4$E.'^@T<G]M]+:MIE(*3IZH
M6;F0==W7W8&TNZ3M:UYPKNCTLI5RL[+U]T][)[TWKO9?]T1FO;"[IF9NSVI%
MW;V6%XIJ*DQN]M9NV"M"5\;N4#0I*W+MP_MFF''RS0[3B]IN[\I2VYK]6"@W
M72D[PV6\USYW49 '9LL].F>M:=R9R>=N0EG7 7 ?<A(Y!?O/][RAJXDVBL2F
MK(F3">5Y_=^MYD#2;:!7)8E'6V-UI_85AWW:#=N5BB.I$JHLZ[(NHN*]8!WO
MG!M%=T&4K:@=SQG?QGFJ9.JCLR$A/1W=!66;:(;FE6T_<7T8<C*KQGD@ ?+L
M80"M=(-%]#W5L6(+QZ4&[)X2R+>/RK?"6\.8RV/G@<Z8ZZ_KBCOE4K<Q/"YX
MB@#!GV*.%$&W2!&X$B(C_($NI*H!OZ\$\OX-DW>5-R3,?V=$&:KX&D+Z2 R$
M_083ML<A$N]'181FC@\$^+$:2/QWU L/CT<DY.,YY=RE<42 ]O(J/1#['YC8
M_3Y? ?B;9W=^MZ<6./N=(D#\?[X6_$=ND2)P3Q63B3VE*P#[(S&0^ADF=8]#
M5-XW(H'2WDK!^0\^[ -[2*B'3,>$%ST:VFTZC+M"#D6.DG/6VD3%_B\E"@Q]
M1PQ%CI*&UEAL&/@@4VJO,\%1Q:^&(D=)0.M,-LS\1AAFUNZ^_^<LG?RX<;K/
M^E@%98R2=/I,H; M[S0(XQYGA/@>*J&,47+-D#D4S@/K1Q$^$@E=?:3K$.@C
M*90T2HX9M(>"^EZQE*CUF,7U@\:Q%@H;);,,&T2A_4A6H\2Z8E-6/!"LA^XM
M F6/DE:"[**$8"1BJ19RYW;Q0&;V>%P/9!(<TFL*0L.!DF^^P#I*4*Z2Q.+2
MFS^W3-!>*!25<O S(KP !&R^$NS]EV'OP[&CY*&U-E\)]M.783^%8T?)16MM
M8F(?V(]WZE$N/4^@O6(H<I1<M,8B)O#\3'.G[I5\9L6\J#KJ1R6@Z!%3U+!9
MU!V^.,E#]O92">6-F*Y6F\/D?"^U(?P_MJB[DJS60YDC)JXAHTW?8"SB[FY:
M^*82'4B@?%%RU4H[32-U$5:4^'???044*$H"6F6F89ZWTCW[F$L1O!][K()R
M1<DD?:::'GC=5&+M/?1WO@;/8$,95@]M-(SQFV+&]F @TS03FWLTGJ=B'BD4
M+TKZ%[37,.JQY"QFAHG9)WN%J!CAU9RK=%#(*,F>WUC#A.\5=9&F]K([G\?E
MUAJHN^G4-_*&]%#B*+E>O5%<\B.M,ZI>RK^B%#0**&D?U'33XPR-,SOLK7O]
MR:-;,>,998Y44-8H*9_/5,-L/\M'1=QZO?$ZG4CN7QY2*8021DGP M8:AKS7
MCVJ\!Q(H6)3,KM(.TIAPLXKG1,RH?_9"M1(*&"73"YE#&WMGH+%W]L*Q%R7C
M\YE"8EO,#;='U-V$LQGQKR0+%@"OL\$D'K#:]/J]?,F/6\FMTKP?0_NA&KM'
M"@6.LT0R9*]IU%G"#$V*+@V9("*V*=5V79LG.Z\O!0T SAI*H&F4V_O?*.<?
MA5R*,25:"IH4E_JA._S>(M H(#Y#K+&+$H*ODF>6DLHG@BK/,>"10I$C/COT
MV,.9>UE,:MZ>>XI7=H2(^TI P2,^1 R;19J?9JCK,WNF[XDAFQZ&^/M*0/DC
M/E ,FT6;/Z\&]L0SD^%GY@="*&W$J;"5UE @CU/"^76FF: Z.+8<"*&0$>>\
M5EI#@7R34C6S@]H')9=FOEG;&8+M*0"%CCBS-6@5!_[JQSKR8OU;D'R%&OQV
M D3L7I-8K]V(8S>1HCB3BX0H#_60'LH==6&EWVC#Y._,G*K=ZZ>\,R.;MX4F
M/=27@D8!)5V%FL8YM^ZLY ^>6O=T4-Z(B6F5,9PU4]F$LWC()0E>E^_)H'P1
ML] *6RAXKXEX4MG"Q.M[)6-*W>,3O3W:  D1L )H2!#STQ>AP+E=(-/4+2:2
M\=-X;DWKN\SD;S"U_0O>- B6@X8&<Q$GP#C259#^L="+)M?K!SJERDU3>*0K
M<VT;>@I?% &*0^.#^D8A,(:*,%UTCWS=V@WN';7%-^Z7>P^KW?(_4$L! A0#
M%     @ %3)05ZF.S&JA$P  "'(  !@              ( !     &5A,3@V
M-S<Y+3AK7VUO;VYL86ME+FAT;5!+ 0(4 Q0    ( !4R4%=11_L^B"   !>Q
M   ;              "  =<3  !E83$X-C<W.65X.3DM,5]M;V]N;&%K92YH
M=&U02P$"% ,4    "  5,E!7,LF3)4@H  ",*0  #0              @ &8
M-   :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( !4R4%>3M9#>*0,  .D+   1
M              "  0M=  !M;'1X+3(P,C,Q,#$U+GAS9%!+ 0(4 Q0    (
M !4R4%?)U'6G_0H  ("&   5              "  6-@  !M;'1X+3(P,C,Q
M,#$U7VQA8BYX;6Q02P$"% ,4    "  5,E!7"MN;7U<'  #95P  %0
M        @ &3:P  ;6QT>"TR,#(S,3 Q-5]P<F4N>&UL4$L%!@     &  8
*CP$  !US      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
